Executive Officers

Blaise Coleman

Blaise Coleman was appointed President, Chief Executive Officer and a member of the Board of Directors, effective March 2020. He previously served as Executive Vice President and Chief Financial Officer since December 2016. He joined Endo in January 2015 as Vice President of Corporate Financial Planning & Analysis, and was then promoted to Senior Vice President, Global Finance Operations in November 2015. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, most recently as the Chief Financial Officer of the AstraZeneca/Bristol-Myers Squibb US Diabetes Alliance. Prior to that, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mölndal, Sweden. Mr. Coleman joined AstraZeneca in 2007 as Senior Director Commercial Finance for the US Cardiovascular Business. He joined AstraZeneca from Centocor, a wholly-owned subsidiary of Johnson & Johnson, where he held positions in both the Licenses & Acquisitions and Commercial Finance organizations. Mr. Coleman’s move to Centocor in early 2003 followed 7 years’ experience with the global public accounting firm, PricewaterhouseCoopers LLP. Mr. Coleman is a Certified Public Accountant; he holds a Bachelor of Science degree in accounting from Widener University and an M.B.A. from the Fuqua School of Business at Duke University. Mr. Coleman’s qualifications to serve on the Board of Endo include, among others, his executive leadership experience at pharmaceutical companies, extensive background in finance, business and strategic planning and in-depth knowledge of the Company, its businesses and management.

Patrick Barry

Patrick Barry was appointed Executive Vice President and President, Global Commercial Operations, effective April 2020. In this role, he has responsibility for the Company’s global commercial organization across each of Endo’s four reportable business segments, including Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. He formerly served as Executive Vice President and Chief Commercial Officer, U.S. Branded Business since February 2018, after joining Endo in December 2016 as Senior Vice President, U.S. Branded Pharmaceuticals. Prior to joining Endo, Mr. Barry worked at Sanofi S.A. from 1992 until December 2016, holding roles of increasing responsibility in areas such as Sales Leadership, Commercial Operations, Marketing, Launch Planning and Training and Leadership Development. Most recently, he served at Sanofi S.A. as its General Manager and Head of North America General Medicines starting in September 2015 and as Vice President and Head of U.S. Specialty from April 2014 until August 2015. During this time, Mr. Barry oversaw three complex and diverse businesses with responsibility for leading sales and marketing activities for branded and generic products across the U.S. and Canada. He has a diverse therapeutic experience including aesthetics and dermatology, oncology, urology, orthopedics and medical device and surgical experience. He has an M.B.A. from Cornell University, Johnson School of Management and a B.A. in Public Relations and Marketing from McKendree University.

Tracy Basso

Tracy Basso was appointed Chief Human Resources Officer effective July 1, 2019. In this role she leads all aspects of human resources in enabling the development and growth of Endo. Most recently Ms. Basso, who joined the company in November 2004, was Senior Vice President Human Resources, leading human resources support for the Company’s sterile injectable and generic businesses as well as operations, quality and enterprise-wide Talent Acquisition. Prior to joining the company, Ms. Basso, who has over 20 years of experience in human resources, worked for GlaxoSmithKline and started her career at Best Foods Baking Company. She holds a Master’s in Human Resources from Fordham University and a Bachelor of Science in Business Management from Iona College.

Mark Bradley

Mark Bradley was appointed Executive Vice President and Chief Financial Officer, effective March 2020. He previously served as Senior Vice President, Corporate Development & Treasurer since June 2017. Mr. Bradley joined Endo in January 2007 as a Finance Director and has held various positions of increasing responsibility since joining the Company. Prior to joining Endo, he spent nearly 7 years as a management consultant, most recently with Deloitte Consulting, providing a broad range of strategic and operational advice and services to senior executives across a number of industries. In addition, Mr. Bradley served as a Finance Director for an industrial products company for approximately 2 years. He spent the first 5 years of his career in public accounting at Ernst & Young LLP. Mr. Bradley is a licensed Certified Public Accountant and holds a Bachelor of Science degree in Accounting from Saint Joseph’s University and a Master of Business Administration from The University of Texas at Austin.

Matthew J. Maletta

Matthew J. Maletta was appointed Executive Vice President and Chief Legal Officer, effective May 2015, where he has global responsibility for all legal matters affecting the Company. He was also appointed Company Secretary, effective June 2020. Prior to joining Endo in 2015, Mr. Maletta served as Vice President, Associate General Counsel and Corporate Secretary of Allergan. In this position, he served as an advisor to the Chief Executive Officer and Board of Directors and supervised several large transactions, including the $70 billion acquisition of Allergan by Actavis in 2015. Mr. Maletta also played a key role defending Allergan from an unsolicited takeover bid by Valeant Pharmaceuticals and Pershing Square Capital Management in 2014. Mr. Maletta joined Allergan in 2002 and during his tenure, held roles of increased responsibility, including serving as the lead commercial attorney for Allergan’s aesthetics businesses for several years and as Head of Human Resources in 2010. Prior to joining Allergan, Mr. Maletta was in private practice, focusing on general corporate matters, finance, governance, securities and transactions. He holds a B.A. degree in political science from the University of Minnesota, summa cum laude and Phi Beta Kappa, and a J.D. degree, cum laude, from the University of Minnesota Law School.

Mick McGuinness

Michael (Mick) McGuinness was appointed Global Head of Quality and Compliance, effective June 2022. In this role, Mr. McGuinness has responsibility for the Company’s overall global quality and compliance. Since joining Endo in 2014, he has provided critical leadership and technical insight to the strategy, design and implementation of quality systems and processes that are critical to Endo’s ability to consistently deliver hiqh-quality medicines. Mr. McGuinness brings more than 30 years of experience in quality, technical and manufacturing roles of increasing responsibility on multiple continents. He is a Graduate of the Royal Society of Chemistry, having studied at the University of Hertfordshire.

James Papp

James Papp was appointed Head of Endo Ventures Limited & Senior Vice President, Global Supply Chain in November 2020.  In this role Mr. Papp is responsible for the overall strategic management and operations of Endo Ventures Limited, Ireland and the strategic management and operations of the Endo’s global supply chain.  Mr. Papp joined Endo in October 2019 as Senior Vice President, Global Supply Operations at Endo Ventures Limited, Ireland.  Mr. Papp has over 35 years of leadership experience in pharmaceutical global supply chain management, strategic sourcing, supplier management, contract manufacturing and continuous improvement in organizations such as Mylan, Novartis, Par Pharmaceutical, and Schering Plough. Jim earned his Bachelors degree in Business Administration from the University of Scranton, Scranton PA (USA) in 1981, and his MBA in Pharmaceutical Studies at Fairleigh Dickinson University in Madison, NJ (USA) in 1990.

Laure Park

Laure Park was appointed Senior Vice President, Investor Relations and Corporate Affairs effective August 2, 2018. In this role, Ms. Park is responsible for leading Endo’s Investor Relations and Corporate Affairs teams, including ESG, internal communications and engagement, as well as corporate communications, branding and public relations. Prior to joining Endo, Ms. Park spent 23 years at Quest Diagnostics where she held key leadership roles in different functional areas including finance, investor relations and communications. Most recently, she served as Quest Diagnostics’ Vice President, Customer Experience, where she was responsible for building a customer-focused culture and representing the customer in the design and delivery of the customer experience. Prior to that, Ms. Park was Vice President of Communications & Investor Relations, responsible for leading investor relations and integrating it with the internal and external communications functions. She also served as the Vice President & General Manager of their Prescription Drug Monitoring business. Ms. Park began her career in public accounting with Deloitte. She holds bachelors' degrees in Accounting and Communications from the University of North Dakota.

Michael Randolph

Michael Randolph was appointed Global Head of Manufacturing Operations effective June 2022. Most recently, he served as Senior Vice President, Commercial Operations and General Manager, and was responsible for U.S. operations. He brings more than 30 years of global pharmaceutical manufacturing operations experience to the role as well as a passion for process improvement and quality. Prior to joining Endo in 2015, Mr. Randolph had roles of increasing responsibility at Fujifilm, Mylan, Teva and Baxter Healthcare. Mr. Randolph holds a Master of Science in Civil Engineering from Georgia Institute of Technology and a Bachelor of Science in Civil Engineering from North Carolina State University.

Cheryl Stouch

Cheryl Stouch was appointed Senior Vice President, Information Technology and Chief Information Officer, effective June 2022. In this role, she has responsibility for the overall IT strategy and roadmap to support Endo’s business strategy and vision, ensuring digital capabilities for all global operations and team members. She joined Endo in May 2020 as Executive Director of IT Corporate Functions & End User Services. Since joining Endo, Ms. Stouch has championed the development and implementation of our enterprise collaboration strategy and is the Co-chair and a founding member of AWE (Alliance for Women at Endo). Prior to joining Endo, Ms. Stouch spent 13 years at Shire (now Takeda), where she held various positions of increasing responsibility within IT, partnering with leaders from across the business. Her most recent role at Shire was Head of IT Cross Function & Platforms, where she was accountable for eight Global Enterprise Capabilities supporting 32k team members. Ms. Stouch began her career in the food industry and then in management consulting, working for IBM focused on SAP Enterprise Solutions. Ms. Stouch is a member of the Healthcare Businesswomen’s Association (HBA). She holds a Bachelor of Business and a Bachelor of Science for Information Systems from Dakota State University.

James Tursi

James Tursi, M.D., was appointed Executive Vice President, Global Research & Development, effective January 2022. In this role, Dr. Tursi is responsible for leading global research & development, medical affairs and regulatory operations. Prior to joining Endo, he held senior leadership roles at Ferring Pharmaceuticals U.S., Antares Pharmaceuticals and Aralez Pharmaceuticals. Prior to Aralez, Dr. Tursi was Chief Medical Officer and Vice President of Clinical R&D at Auxilium Pharmaceuticals until its acquisition by Endo in 2015. Dr. Tursi practiced medicine and surgery for over 10 years and created a medical education company, I Will Pass®, which assisted physicians in the process of board certification. He performed his residency in Gynecology and Obstetrics at the Johns Hopkins Hospital, holds a Bachelor of Science degree in Chemistry and Biology from Ursinus College, and a Doctor of Medicine degree from the Medical College of Pennsylvania. Dr. Tursi is a member of the Ideal Image Board of Directors. Previously, Dr. Tursi served as a member of the Agile Therapeutics, Inc. Board of Directors from October 2014 to October 2022.

Susan Williamson

Susan Williamson was appointed Senior Vice President and Chief Compliance Officer effective April 1, 2018. In this role, she is responsible for the strategic direction and operations of Endo's Global Corporate Compliance program. Ms. Williamson joined Endo in 2012 and has been a valued member of Endo's Corporate Compliance leadership team, previously serving as Endo's Vice President and U.S. and Canadian Compliance Officer where she was responsible for oversight of Endo's Corporate Compliance program including management of Endo's Corporate Integrity Agreement (CIA), enterprise wide corporate compliance training and monitoring and Aggregate Spend reporting. Prior to joining Endo, Ms. Williamson worked at Pfizer in Operational Risk Management supporting Pfizer's CIA from 2009 to 2012. Prior to her employment with Pfizer, Ms. Williamson spent over five years at Wyeth Pharmaceuticals and held key roles in building, developing and implementing a Global Corporate Compliance program. Ms. Williamson began her career in public accounting at Ernst & Young in the Assurance and Advisory Practice. Ms. Williamson is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting from Saint Joseph's University as well as an M.B.A. from the Erivan K. Haub School of Business at St. Joseph's University.